130 related articles for article (PubMed ID: 10098667)
1. Design, synthesis, and evaluation of azapeptides as substrates and inhibitors for human rhinovirus 3C protease.
Venkatraman S; Kong J; Nimkar S; Wang QM; Aubé J; Hanzlik RP
Bioorg Med Chem Lett; 1999 Feb; 9(4):577-80. PubMed ID: 10098667
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication.
Kong JS; Venkatraman S; Furness K; Nimkar S; Shepherd TA; Wang QM; Aubé J; Hanzlik RP
J Med Chem; 1998 Jul; 41(14):2579-87. PubMed ID: 9651162
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.
Namoto K; Sirockin F; Sellner H; Wiesmann C; Villard F; Moreau RJ; Valeur E; Paulding SC; Schleeger S; Schipp K; Loup J; Andrews L; Swale R; Robinson M; Farady CJ
Bioorg Med Chem Lett; 2018 Mar; 28(5):906-909. PubMed ID: 29433930
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Fuhrman SA; Patick AK; Matthews DA; Ford CE; Meador JW; Ferre RA; Worland ST
J Med Chem; 1999 Apr; 42(7):1203-12. PubMed ID: 10197964
[TBL] [Abstract][Full Text] [Related]
5. Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation.
Reich SH; Johnson T; Wallace MB; Kephart SE; Fuhrman SA; Worland ST; Matthews DA; Hendrickson TF; Chan F; Meador J; Ferre RA; Brown EL; DeLisle DM; Patick AK; Binford SL; Ford CE
J Med Chem; 2000 May; 43(9):1670-83. PubMed ID: 10794684
[TBL] [Abstract][Full Text] [Related]
6. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.
Matthews DA; Dragovich PS; Webber SE; Fuhrman SA; Patick AK; Zalman LS; Hendrickson TF; Love RA; Prins TJ; Marakovits JT; Zhou R; Tikhe J; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; Brothers MA; DeLisle DM; Worland ST
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11000-7. PubMed ID: 10500114
[TBL] [Abstract][Full Text] [Related]
7. Non-covalent inhibitors of rhinovirus 3C protease.
Baxter A; Chambers M; Edfeldt F; Edman K; Freeman A; Johansson C; King S; Morley A; Petersen J; Rawlins P; Spadola L; Thong B; Van de Poël H; Williams N
Bioorg Med Chem Lett; 2011 Jan; 21(2):777-80. PubMed ID: 21183345
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
Dragovich PS; Prins TJ; Zhou R; Webber SE; Marakovits JT; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Ford CE; Burke BJ; Rejto PA; Hendrickson TF; Tuntland T; Brown EL; Meador JW; Ferre RA; Harr JE; Kosa MB; Worland ST
J Med Chem; 1999 Apr; 42(7):1213-24. PubMed ID: 10197965
[TBL] [Abstract][Full Text] [Related]
9. A simple solid phase, peptide-based fluorescent assay for the efficient and universal screening of HRV 3C protease inhibitors.
Schünemann K; Connelly S; Kowalczyk R; Sperry J; Wilson IA; Fraser JD; Brimble MA
Bioorg Med Chem Lett; 2012 Aug; 22(15):5018-24. PubMed ID: 22763202
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids.
Dragovich PS; Webber SE; Prins TJ; Zhou R; Marakovits JT; Tikhe JG; Fuhrman SA; Patick AK; Matthews DA; Ford CE; Brown EL; Binford SL; Meador JW; Ferre RA; Worland ST
Bioorg Med Chem Lett; 1999 Aug; 9(15):2189-94. PubMed ID: 10465543
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Johnson TO; Brown EL; Maldonado FC; Fuhrman SA; Zalman LS; Patick AK; Matthews DA; Hou X; Meador JW; Ferre RA; Worland ST
Bioorg Med Chem Lett; 2002 Mar; 12(5):733-8. PubMed ID: 11858991
[TBL] [Abstract][Full Text] [Related]
12. Citrinin hydrate and radicinin: human rhinovirus 3C-protease inhibitors discovered in a target-directed microbial screen.
Kadam S; Poddig J; Humphrey P; Karwowski J; Jackson M; Tennent S; Fung L; Hochlowski J; Rasmussen R; McAlpine J
J Antibiot (Tokyo); 1994 Jul; 47(7):836-9. PubMed ID: 8071130
[No Abstract] [Full Text] [Related]
13. Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases.
Ekici OD; Götz MG; James KE; Li ZZ; Rukamp BJ; Asgian JL; Caffrey CR; Hansell E; Dvorák J; McKerrow JH; Potempa J; Travis J; Mikolajczyk J; Salvesen GS; Powers JC
J Med Chem; 2004 Apr; 47(8):1889-92. PubMed ID: 15055989
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.
Dragovich PS; Zhou R; Webber SE; Prins TJ; Kwok AK; Okano K; Fuhrman SA; Zalman LS; Maldonado FC; Brown EL; Meador JW; Patick AK; Ford CE; Brothers MA; Binford SL; Matthews DA; Ferre RA; Worland ST
Bioorg Med Chem Lett; 2000 Jan; 10(1):45-8. PubMed ID: 10636240
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Reich SH; Prins TJ; Marakovits JT; Littlefield ES; Zhou R; Tikhe J; Ford CE; Wallace MB; Meador JW; Ferre RA; Brown EL; Binford SL; Harr JE; DeLisle DM; Worland ST
J Med Chem; 1998 Jul; 41(15):2806-18. PubMed ID: 9667970
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.
Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Reich SH; Marakovits JT; Prins TJ; Zhou R; Tikhe J; Littlefield ES; Bleckman TM; Wallace MB; Little TL; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; DeLisle DM; Worland ST
J Med Chem; 1998 Jul; 41(15):2819-34. PubMed ID: 9667971
[TBL] [Abstract][Full Text] [Related]
17. Human rhinovirus 3C protease as a potential target for the development of antiviral agents.
Wanga QM; Chen SH
Curr Protein Pept Sci; 2007 Feb; 8(1):19-27. PubMed ID: 17305557
[TBL] [Abstract][Full Text] [Related]
18. S-nitrosothiols as novel, reversible inhibitors of human rhinovirus 3C protease.
Xian M; Wang QM; Chen X; Wang K; Wang PG
Bioorg Med Chem Lett; 2000 Sep; 10(18):2097-100. PubMed ID: 10999479
[TBL] [Abstract][Full Text] [Related]
19. New anti-viral drugs for the treatment of the common cold.
Maugeri C; Alisi MA; Apicella C; Cellai L; Dragone P; Fioravanzo E; Florio S; Furlotti G; Mangano G; Ombrato R; Luisi R; Pompei R; Rincicotti V; Russo V; Vitiello M; Cazzolla N
Bioorg Med Chem; 2008 Mar; 16(6):3091-107. PubMed ID: 18248816
[TBL] [Abstract][Full Text] [Related]
20. Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease.
Kawatkar SP; Gagnon M; Hoesch V; Tiong-Yip C; Johnson K; Ek M; Nilsson E; Lister T; Olsson L; Patel J; Yu Q
Bioorg Med Chem Lett; 2016 Jul; 26(14):3248-3252. PubMed ID: 27265257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
